Roche forges deal with San Diego biotech, bet­ting on new an­tibi­ot­ic class

The coro­n­avirus out­break may be mo­nop­o­liz­ing the air­waves, but that doesn’t mean the tsuna­mi of an­tibi­ot­ic re­sis­tance isn’t still in­com­ing.

But there is some en­cour­ag­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER